Thymic Tumors
Summary of Key Points • Thymic tumors are rare malignancies and represent a wide array of tumors. • Histologic classification distinguishes three separate entities: thymomas, thymic carcinomas, and neuroendocrine thymic…
Palliative Radiotherapy for Lung Cancer
Summary of Key Points • Palliative radiotherapy is an effective and well tolerated treatment for palliation of thoracic and other symptoms in patients with lung cancer (both nonsmall cell lung…
Management of Toxicities of Targeted Therapies
Summary of Key Points • Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, C-ros oncogene 1 (ROS1), ret proto-oncogene (RET) tyrosine kinase inhibitors (TKIs), several antiangiogenesis agents, and…
Maintenance Chemotherapy for Nonsmall Cell Lung Cancer
Summary of Key Points • Maintenance therapy offers the possibility of continued active treatment to delay disease progression and symptom deterioration and, more importantly, improved overall survival of patients with…
Pharmacogenomics in Lung Cancer: Predictive Biomarkers for Chemotherapy
Summary of Key Points • Discussed are tumor factors that affect treatment responses and outcome and host genetic elements that affect drug metabolism. Only pharmacogenomics elements that interact with chemotherapeutic…
Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer
Abstract Surgery is the recommended treatment modality for patients with non-small cell lung cancer (NSCLC) stage I-II. Meta-analyses of randomized studies demonstrates a survival benefit with adjuvant chemotherapy—including neo-adjuvant chemotherapy—for…
Mediastinal Tumors
Summary of Key Points • Knowledge of the anatomy of the mediastinum is critical to establishing the differential diagnosis and choosing the best diagnostic and therapeutic interventions. • A wide…
Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer
Keywords ALK, biomarkers, chemotherapy, cisplatin, EGFR, immune checkpoint inhibition, PD-1, pemetrexed Summary of Key Points • The determination of tumor histology in nonsmall cell lung cancer (NSCLC) has become…
Systemic Options for Second-Line Therapy and Beyond
Summary of Key Points • There are a growing proportion of patients who are candidates for second-line therapy and beyond. • Treatment choices are dictated by tumor histology, molecular phenotype…
New Targets for Therapy in Lung Cancer
Summary of Key Points • Treatment of lung cancer is rapidly evolving. Large cell carcinomas as a group have therapeutically relevant driver mutations in nearly 40% of cases. • Despite…
